Rhythmic Risk of Type 1 Brugada Syndrome and Pulmonary Infundibulum Mapping

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Brugada syndrome has been described as the association of a right bundle block with ST segment elevation on the V1 to V3 electrocardiogram in patients with a structurally normal heart. The rhythmic risk is thus difficult to evaluate in asymptomatic patients in whom the rate of events is estimated at 0.2 to 1.4% of events per year. In addition, the predictive value of ventricular pacing remains controversial; There is therefore currently no review to effectively assess rhythmic risk in patients with Brugada type I syndrome.

Investigators aimed to show a difference in pulmonary infundibulum voltage mapping in symptomatic and asymptomatic patients with Brugada type 1 syndrome with a comparable ECG.

The mapping of the pulmonary infundibulum will be performed during electrophysiological exploration. Only the catheter used differs from the usual procedure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AnalyST & Brugada Syndrome - Feasibility Study

NCT02052765

Brugada Syndrome

COMPLETED NA

Non-invasive Mapping of Rhythm Disorders

NCT02647749

Cardiac Rhythm Disorders

COMPLETED NA

High Density Mapping in Brugada Syndrome

NCT06567639

Brugada Syndrome

COMPLETED

Ripple Mapping for Epicardial Mapping of Brugada Syndrome

NCT03435393

Brugada Syndrome

UNKNOWN

Mapping and Pacing of the His Bundle for Heart Failure Patients With Left Bundle Branch Block

NCT03803995

Heart Failure Left Bundle-Branch Block

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brugada Syndrome Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asymptomatic

Group Type EXPERIMENTAL

Endocardial mapping

Intervention Type DEVICE

An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.

Symptomatic

Group Type EXPERIMENTAL

Endocardial mapping

Intervention Type DEVICE

An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endocardial mapping

An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 21

* Brugada Type 1 syndrome
* Age : 50-60 years old
* Asymptomatic
* Signed informed consent

Group2

* Brugada Type 1 syndrome
* Age \>18 years old
* Implantable defibrillator
* Having received at least 1 appropriate shock or a sudden sudden death
* Signed informed consent

Groups 1 and 2